For CRP levels of 8 mg/L or higher, ApoE4 carriers had a fivefold to 10-fold increase of risk of AD risk compared with ApoE3 and ApoE2 carriers (7 of 27 [25.9%] vs 7 of 132 [5.3%] vs 1 of 42 [2.4%]; P = .002). Here, CRP is linked to Alzheimer disease.